Important Update for MoonLake (MLTX) Investors
In a concerning turn of events, investors are being urged to pay close attention to the ongoing class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX). With the critical Lead Plaintiff Deadline approaching, now is the time for affected parties to take action.
Understanding the Lawsuit
The core of the lawsuit revolves around allegations that MoonLake and its executives provided materially misleading statements about their drug candidate, sonelokimab (SLK). These claims reportedly led to a drastic decline in stock value, plummeting nearly 90% when disappointing Phase 3 trial results were revealed.
Nanobody Technology Claims Under Scrutiny
At the heart of these allegations is MoonLake's assertion that SLK's unique Nanobody structure would result in superior efficacy compared to traditional monoclonal antibody treatments, specifically targeting the FDA-approved BIMZELX. Investors were promised enhanced effectiveness, which failed to materialize as the results from the VELA-2 trial showed inferior results.
Reed Kathrein, the partner leading this litigation at Hagens Berman, commented on the situation, stating that the promises about Nanobody technology vanished once the trial results were disclosed, leading to significant financial losses for investors.
Key Details of the Lawsuit
The timeline for the alleged acts is crucial. Investors who held shares between the specific dates outlined in the class period may have grounds for this claim. The following points summarize the critical elements:
- Issuer: MoonLake Immunotherapeutics (MLTX)
- Class Period: March 10, 2024 – September 29, 2025
- Lead Plaintiff Deadline: December 15, 2025
- Stock Drop Event: The stock's value fell from $61.99 to $6.24, representing a shocking 90% decline on September 29, 2025, after the VELA-2 trial failed to meet its primary endpoint.
Next Steps for Affected Investors
Investors who suffered significant losses from their investments in MoonLake stock (MLTX) during the specified period are strongly advised to reach out to Hagens Berman as soon as possible. They can explore their legal options and consider being designated as Lead Plaintiff in the case.
How to Submit Your Losses
The firm has provided a secure form for investors to submit their losses directly. By doing so, individuals can initiate the process of seeking justice and compensation for their financial setbacks.
Contact and Whistleblower Information
Hagens Berman encourages individuals with knowledge about non-public information related to MoonLake to contact them. The firm emphasizes that whistleblowers may receive rewards through the SEC Whistleblower program for providing original information that leads to successful recoveries.
Those interested can reach out to Reed Kathrein, who is leading the investigation, via phone at 844-916-0895 for any inquiries or to share information that could assist the lawsuit.
Frequently Asked Questions
What is the primary allegation in the MoonLake lawsuit?
The lawsuit alleges that MoonLake executives made misleading statements about their drug SLK's potential, leading to significant financial losses for investors.
When is the deadline for the Lead Plaintiff in the case?
The Lead Plaintiff Deadline is set for December 15, 2025. Investors should act swiftly to secure their position.
What caused the stock price to drop significantly?
The stock price dropped nearly 90% following the release of disappointing results from the VELA-2 clinical trial.
How can investors submit their losses?
Investors can submit their claims through a secure form provided by Hagens Berman to participate in the class action lawsuit.
Where can I find more information about MoonLake and the lawsuit?
Additional information can be found by contacting Hagens Berman or through their website, where updates about the case are regularly posted.
